James D Levine
Overview
Explore the profile of James D Levine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Permpalung N, Mahoney M, McCoy C, Atsawarungruangkit A, Gold H, Levine J, et al.
Leuk Lymphoma
. 2018 Jun;
60(1):85-91.
PMID: 29947555
Palivizumab has been used to treat respiratory syncytial virus (RSV)-infected hematologic malignancy patients at our institution based on limited published data. We conducted this retrospective study to evaluate clinical outcomes...
2.
Nahas M, Soiffer R, Kim H, Alyea 3rd E, Arnason J, Joyce R, et al.
Blood
. 2018 Mar;
131(25):2836-2845.
PMID: 29549175
Steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. Innovative immunotherapeutic strategies are urgently needed for the treatment of SR-cGVHD. We...
3.
Soiffer R, Kim H, McGuirk J, Horwitz M, Johnston L, Patnaik M, et al.
J Clin Oncol
. 2017 Oct;
35(36):4003-4011.
PMID: 29040031
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a...
4.
Rosenblatt J, Stone R, Uhl L, Neuberg D, Joyce R, Levine J, et al.
Sci Transl Med
. 2016 Dec;
8(368):368ra171.
PMID: 27928025
We developed a personalized cancer vaccine in which patient-derived acute myeloid leukemia (AML) cells are fused with autologous dendritic cells, generating a hybridoma that potently stimulates broad antitumor responses. We...
5.
Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, et al.
Cancer Res
. 2013 Jul;
73(17):5569-79.
PMID: 23867470
Acute myeloid leukemia (AML) is a malignancy of stem cells with an unlimited capacity for self-renewal. MUC1 is a secreted, oncogenic mucin that is expressed aberrantly in AML blasts, but...
6.
Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi N, Katz T, et al.
Clin Cancer Res
. 2013 May;
19(13):3640-8.
PMID: 23685836
Purpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on...
7.
Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, et al.
Cancer Immunol Immunother
. 2012 Jun;
62(1):39-49.
PMID: 22733396
Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits immunomodulatory properties including the activation of T and NK cells. The use of lenalidomide to reverse tumor-mediated immune suppression...
8.
Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine J, et al.
J Immunother
. 2011 May;
34(5):409-18.
PMID: 21577144
We have developed a cancer vaccine in which autologous tumor is fused with dendritic cells (DCs) resulting in the presentation of tumor antigens in the context of DC-mediated costimulation. In...
9.
Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, et al.
Blood
. 2010 Oct;
117(2):393-402.
PMID: 21030562
We have developed a tumor vaccine in which patient-derived myeloma cells are chemically fused with autologous dendritic cells (DCs) such that a broad spectrum of myeloma-associated antigens are presented in...
10.
Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, et al.
J Immunother
. 2010 Feb;
33(2):155-66.
PMID: 20145548
Adoptive immunotherapy with tumor-specific T cells represents a promising treatment strategy for patients with malignancy. However, the efficacy of T-cell therapy has been limited by the ability to expand tumor-reactive...